Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria M Rubinstein

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Current Opinion in Obstetrics & Gynecology|December 14, 2019
Optimizing immunotherapy for gynecologic cancersMaria M Rubinstein, Vicky Makker
British Journal of Cancer|April 29, 2021
Targeting obesity-related dysfunction in hormonally driven cancersMaria M Rubinstein, Kristy A Brown, Neil M Iyengar
Gynecologic Oncology Reports|August 25, 2021
Sustained response to lenvatinib and pembrolizumab in two patients with <i>KRAS</i>-mutated endometrial mesonephric-like adenocarcinomaSherry Shen, Maria M Rubinstein, Kay J Park, et al.
Journal of Gastrointestinal Oncology|January 5, 2018
Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantationMaria M Rubinstein, Andreas Kaubisch, Milan Kinkhabwala, et al.
Clinical Case Reports|March 5, 2020
Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's WitnessMaria M Rubinstein, Cheryl Goss, Scott T Avecilla, et al.
Gynecologic Oncology|April 25, 2021
Bevacizumab in advanced endometrial cancerMaria M Rubinstein, Shannan Dickinson, Priyanka Narayan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 25, 2025
Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatmentMichelle D S Lightfoot, Maria M Rubinstein, Bradley J Monk, et al.
Gynecologic Oncology Reports|December 20, 2021
Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for <i>BRCA1/2</i>-associated ovarian cancerAnastasia Navitski, Duaa H Al-Rawi, Ying Liu, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|June 4, 2024
Novel Androgen Receptor Splice Variant 7 in Gynecologic TumorsLucy Wang, Varshini Vasudevaraja, Ivy Tran, et al.
Gynecologic Oncology|September 25, 2023
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancerWilliam A Zammarrelli, Weining Ma, Kevin Espino, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Current Opinion in Obstetrics & Gynecology|December 14, 2019
Optimizing immunotherapy for gynecologic cancersMaria M Rubinstein, Vicky Makker
British Journal of Cancer|April 29, 2021
Targeting obesity-related dysfunction in hormonally driven cancersMaria M Rubinstein, Kristy A Brown, Neil M Iyengar
Gynecologic Oncology Reports|August 25, 2021
Sustained response to lenvatinib and pembrolizumab in two patients with <i>KRAS</i>-mutated endometrial mesonephric-like adenocarcinomaSherry Shen, Maria M Rubinstein, Kay J Park, et al.
Journal of Gastrointestinal Oncology|January 5, 2018
Bridging therapy effectiveness in the treatment of hepatocellular carcinoma prior to orthotopic liver transplantationMaria M Rubinstein, Andreas Kaubisch, Milan Kinkhabwala, et al.
Clinical Case Reports|March 5, 2020
Management of thymoma-associated pure red cell aplasia: A novel use of blood substitute HBOC-201 in a Jehovah's WitnessMaria M Rubinstein, Cheryl Goss, Scott T Avecilla, et al.
Gynecologic Oncology|April 25, 2021
Bevacizumab in advanced endometrial cancerMaria M Rubinstein, Shannan Dickinson, Priyanka Narayan, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 25, 2025
Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatmentMichelle D S Lightfoot, Maria M Rubinstein, Bradley J Monk, et al.
Gynecologic Oncology Reports|December 20, 2021
Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for <i>BRCA1/2</i>-associated ovarian cancerAnastasia Navitski, Duaa H Al-Rawi, Ying Liu, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|June 4, 2024
Novel Androgen Receptor Splice Variant 7 in Gynecologic TumorsLucy Wang, Varshini Vasudevaraja, Ivy Tran, et al.
Gynecologic Oncology|September 25, 2023
Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancerWilliam A Zammarrelli, Weining Ma, Kevin Espino, et al.
Pageof 3